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PANCREAS
Molecular consequences of cystic fibrosis transmembrane
regulator (CFTR) gene mutations in the exocrine pancreas
N Ahmed, M Corey, G Forstner, J Zielenski, L-C Tsui, L Ellis, E Tullis, P Durie
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Gut 2003;52:1159–1164
Background and aims: We tested the hypothesis that the actual or predicted consequences of muta-
tions in the cystic fibrosis transmembrane regulator gene correlate with the pancreatic phenotype and
with measures of quantitative exocrine pancreatic function.
Methods: We assessed 742 patients with cystic fibrosis for whom genotype and clinical data were
available. At diagnosis, 610 were pancreatic insufficient, 110 were pancreatic sufficient, and 22
pancreatic sufficient patients progressed to pancreatic insufficiency after diagnosis.
Results: We identified mutations on both alleles in 633 patients (85.3%), on one allele in 95 (12.8%),
and on neither allele in 14 (1.9%). Seventy six different mutations were identified. The most common
mutation was ∆F508 (71.3%) followed by G551D (2.9%), G542X (2.3%), 621+1G→T (1.2%), and
W1282X (1.2%). Patients were categorized into five classes according to the predicted functional
consequences of each mutation. Over 95% of patients with severe class I, II, and III mutations were
pancreatic insufficient or progressed to pancreatic insufficiency. In contrast, patients with mild class IV
and V mutations were consistently pancreatic sufficient. In all but four cases each genotype correlated
exclusively with the pancreatic phenotype. Quantitative data of acinar and ductular secretion were
available in 93 patients. Patients with mutations belonging to classes I, II, and III had greatly reduced
acinar and ductular function compared with those with class IV or V mutations.
Conclusion: The predicted or known functional consequences of specific mutant alleles correlate with
the severity of pancreatic disease in cystic fibrosis.
Cystic fibrosis (CF) affects multiple organs, including thepancreas, intestine, sweat gland, and the respiratorytract. Identification of the cystic fibrosis gene1–3 led to
the elucidation of its protein product, the cystic fibrosis trans-
membrane conductance regulator (CFTR), a cAMP regulated
chloride channel.4 Mutations in the CFTR gene result in absent
or defective CFTR chloride channel function at the apical sur-
face of epithelial cells. The most common disease causing
mutation, which accounts for 66–70% of CF chromosomes
worldwide, gives rise to a deletion of a single amino acid,
phenylalanine, at position 508 (∆F508) of the CFTR product.2
More than 1000 additional mutations (http//
www.genet.sickkids.on.ca/cftr/mutations.html) or putative
mutations in the CFTR gene have been identified, all of which
are uncommon or rare.
Infants with CF have progressive pancreatic damage
leading to signs and symptoms of maldigestion due to pancre-
atic insufficiency (PI). However, 10–15% of patients retain
adequate pancreatic reserve to permit normal digestion with-
out enzyme therapy.5 6 In general, those with the “pancreatic
sufficient” (PS) phenotype have less severe disease
manifestations.6 We have previously shown that there is a
strong clinical association between phenotype and genotype
in the exocrine pancreas.7 8 Initial investigations into the
phenotype-genotype relationships in CF were made by study-
ing the clinical phenotype and then making an assumption
regarding the genotype. For example, R117H was noted to be
present in PS patients and therefore an assumption was made
that this was a mild mutation.9 From these studies it was
determined that most individuals with PI have two severe CFTR
mutations while those with the PS phenotype have one or two
mildmutations. However, this correlation was limited as it was
not based on the molecular mechanisms of the specific muta-
tions. In this study, we attempt to overcome this limitation by
classifying the CFTRmutations based on their functional con-
sequences, and then evaluating the relationship with the pan-
creatic phenotype.
CFTR gene mutations can be classified according to their
predicted effects on CFTR mediated anion secretion.9–11 In a
five class system, mutations belonging to classes I, II, and III
are predicted to have severe functional consequences on CFTR
function via different molecular mechanisms. Mutations
belonging to classes IV and V on the other hand are expected
to confer some residual CFTR mediated channel function and
to have milder consequences.
It is our hypothesis that the molecular consequences of
CFTR gene mutations correlate with the exocrine pancreatic
phenotype in patients with CF. The purpose of this analysis
was to validate previous studies of the phenotype-genotype
relationship by starting from the basic molecular mechanisms
and then evaluating the link with the clinical phenotype. In
this report, we present unique data describing the relationship
between the predicted consequences of mutations of the CFTR
gene and quantitative exocrine pancreatic disease in patients
with CF.
METHODS
Patient ascertainment
We assessed all patients with CF attending the Toronto clinics
who had undergone genotype analysis. The diagnosis of CF
was based on the 1998 consensus conference criteria.12 Each
patient’s clinical data and genotype had been recorded in a
computerised database. Each patient’s pancreatic status (PS or
PI) at diagnosis and subsequent changes in pancreatic status
(PS→PI) were defined. Patients who had undergone pancre-
atic stimulation testing were selected for further analysis of
the relationship between exocrine pancreatic function and
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genotype. The study was approved by the institutional ethics
review board.
Assessment of exocrine pancreatic function
Pancreatic function was assessed by one or more of the
following methods.
Faecal fat
Three to five day pooled stool collections were stored at 4°C,
and faecal fat content was determined by the method of van
de Kamer and Weyers13 or by the method of Jeejeebhoy and
Kozak.14 Faecal fat losses, expressed as a percentage of mean
daily fat intake, were calculated by weighing food intake and
by reference to standard food content tables. PI was defined as
faecal fat losses exceeding 7% of measured fat intake in
patients older than six months, or exceeding 15% in infants
younger than six months of age.15
Serum cationic trypsinogen
This radioimmunoassay test reliably distinguishes patients
with PS from those with PI after seven years of age, as previ-
ously described.16 PS patients with CF have shown widely
fluctuating values within or above the normal range. Infants
with PI have high serum trypsinogen levels which decline to
low or undetectable levels by seven years of age. Patients who
are PS at diagnosis but progress to PI (PS→PI) show a
progressive but delayed decline in serum trypsinogen levels.17
Patients with PS were tested every 6–12 months. If serum
trypsinogen values were declining, or if clinical symptoms
suggested pancreatic failure, confirmatory studies (fat balance
and/or pancreatic stimulation tests) were performed.
Quantitative pancreatic stimulation test
Patients were assessed by a marker perfusion technique.18
Enzymes (colipase, total lipase, and trypsin),18 and fluid19 and
electrolyte (Cl- Na+, HCO3-)20 output were expressed per kg
body weight/hour after correcting for the fractional recovery of
infused marker. Patients were defined as PI if colipase output
was less than 120 u/kg body weight/hour or if trypsin output
was below 50 u/kg body weight/hour. If several tests were per-
formed, the results of the most recent test were used.
Genotype analysis
Genotype analysis was performed using total human genomic
DNA extracted from peripheral blood cells by standard meth-
ods. Each exon of the CFTR gene was amplified by the
polymerase chain reaction and screened by SSCP andMDE gel
analyses.21 Direct sequencing analysis was used to characterise
the DNA sequence of a suspected mutation. Based on
retrospective data, this method is capable of detecting more
than 95% of known CFTR gene mutations. This detection rate
does not include patients with rare unknown mutations or
mutations that may lie outside the boundaries of the CFTR
gene (that is, in regulatory elements).
Genotype classification
Genotypes were classified according to their known or
predicted functional consequences.9–11 With the exception of
patients who were homozygous for ∆F508, most patients were
compound heterozygotes with mutations belonging to more
than one class. We used the functional class of the second
mutation on a ∆F508 background. This approach was used to
evaluate the effect of the second mutation in patients carrying
one ∆F508 mutation. For example, a patient carrying a class I
mutation (for example, G542X) in combination with ∆F508
(class II) was classified as class I although the genotype is in
fact a compound heterozygote of class I/II. As class IV or V
mutations have a dominant effect, patients with these muta-
tions were classified according to the presumed consequences
of the dominant mutation.
Statistical analysis
Patient characteristics are presented as mean (SD) and groups
were compared using the Student’s t test; χ2 tests were used to
compare proportions. Results of the quantitative pancreatic
stimulation test produced several measurements with skewed
distributions and unequal variance estimates in the subgroups
to be compared. Therefore, the Kruskal-Wallis rank sum test22
was used to test subgroup differences in pancreatic secretion
measures.
RESULTS
Patients
We assessed 742 patients with a confirmed clinical diagnosis
of CF who had been followed between 1990 and 1997 (table
1). At diagnosis, 610 (82.2%) were PI and 110 (14.8%) have
remained PS. Twenty two patients, who were PS at diagnosis,
became PI during follow up (PS→PI). As previously
observed,6 7 patients in the PS group were diagnosed at a later
age, had lower mean sweat chloride values, better pulmonary
function, better nutritional status, and a lower mortality than
those with the PI phenotype. There was no significant differ-
ence in sweat chloride, forced expiratory volume in one
second, weight for height, or age of diagnosis between the PI
and PS→PI groups.
Genotype analysis
CFTR gene mutations were identified on both alleles in 633
patients (85.3%) and on one allele in only 95 (12.8%) patients.
Among the group with only one identified mutation, 40 were
PS at diagnosis. No CFTR gene mutations were identified on
either allele in 14 (1.9%) patients, of whom seven were PS at
diagnosis. Seventy six different CFTR gene mutations were
identified among the 1324 chromosomes in 662 families (table
2). The most common mutations were: ∆F508 (in 943
chromosomes, 71.2%), G551D (39, 2.9%), G542X (31, 2.3%),
621+1G→T, W1282X (16, 1.2%), and R117H (11, 0.8%). Less
common mutations included G85E and 5T (n=5 chromo-
somes), A455E and R1162X (n=4 chromosomes), R347,
Y1092X, R334W, and V520F (n=3 chromosomes). In 46 CF
Table 1 Patient demographics
PI PS→PI PS p Value*
Sex (M/F) 348/262 14/8 60/50 0.7
Age at diagnosis (y) 2.3 (4.9) 3.1 (6.5) 9.8 (9.5) 0.001
Sweat chloride (mmol/l) 103 (14) 99 (18) 87 (21) 0.001
Age at assessment (y) 21.0 (10.4) 22.6 (8.4) 27.3 (11.7) 0.03
FEV1 (% predicted) 62.0 (29.4) 65.7 (25.9) 76.2 (28.7) 0.001
Weight (% ideal for height) 99.8 (14.6) 99.9 (16.3) 108.8 (18.3) 0.001
Mortality (%) 16.6 9.1 4.6 0.001
Values are mean (SD).
PI, pancreatic insufficiency; PS, pancreatic sufficiency.
*Comparison between PS and PI cohorts by Student’s t test
1160 Ahmed, Corey, Forstner, et al
www.gutjnl.com
 on 13 November 2006 gut.bmj.comDownloaded from 
chromosomes a mutation was found that was absent in other
tested families, and in 116 CF chromosomes no mutation was
detected.
Analysis of 633 patients with two identified CFTR gene
mutations confirmed our previously documented association
between pancreatic phenotype and severe and mild
genotypes,8 10 and provided further information concerning
the phenotypic effects of more recently identified gene
mutations. Mutations were classified as mild or severe, as pre-
viously described.7 With very few exceptions, two severe muta-
tions conferred PI and one mild mutant allele conferred PS in
a dominant manner. Among the 569 patients carrying two
severemutations, 546 (96.0%) were PI, while 61/62 (98%) with
at least one mild mutation were PS. A subset of patients with
severe mutations on both alleles were PS at diagnosis but pro-
gressed to PI. Only four individuals (0.7%) with two severe
mutations have remained PS. Pancreatic stimulation testing of
one patient (∆F508/∆F508) revealed markedly reduced pan-
creatic acinar function, close to the threshold for developing
PI.18 The three remaining patients were not tested.
Functional consequences of CFTR gene mutations and
pancreatic phenotype
We were able to classify 607 of the 633 patients according to
the predicted consequences of their CFTR gene mutations
(table 2). Patients who did not carry ∆F508 but who were
compound heterozygotes for mutations in different classes
were excluded. Ninety nine per cent (552/557) of
patients with both mutations homozygous or compound
heterozygous for classes I, II, or III were PI at diagnosis (528),
or progressed to PI after diagnosis.19 Only five individuals
with class I, II, or III mutations have remained PS since
diagnosis. This includes one patient who carries the missense
mutation G85E which appears to have an indeterminate
effect on pancreatic phenotype as it has been observed in
patients with PS and PI phenotypes.23 All but one of 49
individuals carrying at least one mutation belonging to
classes IV or V have remained PS. The exception, a patient
with the class IV mutation I1234V, developed PI at the age of
25 years, after symptoms of chronic pancreatitis lasting 10
years.
Table 2 Genotype classification according to the functional consequences of CFTR gene mutations
Pancreatic
status Class I Class II Class III Class IV Class V
PS F1, 875+1G→C(2) F, F (1) F, G551D (1) F, R117H (11) F,3849+10kbC→T (5)
F, G85E2(1) F, R347H (3) F,3272–26A→G (4)
F, S1251N (2) F,A445E (3)
F, D614G (1) F,P574H (2)
F, R347P (1) F,3120G>A (1)
R117H,R117H (1) F, 5T (8)
F, L1335P (1) F,2789+5G→A (1)
F,P67L (1)
F,R347P/R347H (1)
F,V232D(2)
R334W, R334W(1)
PS→PI F,3659delC (1) F,F (15) F,G551D (1) F, I1234V (1)
F,2184insA (1) F,R560T (1)
PI F, G542X (27) F,F (365) F, G551D (28)
F, 621+1G→T (13) F, R560T (7)
F,R553X (7) F, N1303K (9)
F, R1162X (6) F,L1077P (2)
F, 3659delC (5) F, I48T (1)
F, 1717-1G→A (5) F,A559T (1)
F, W1282X (5) F, G85E2(2)
F, 711+1G→T (5) G551D,G551D(1)
F,2184delA(4) F,H199R (1)
W1282X,W1282X (4) F,I1072T(1)
F,Y1092X (3) F,S549 (R75Q) (1)
F,556delA (3)
F, Q493X (3)
F,4016InsT (3)
F, 3120+1G→A (2)
F, G551D/R553X (2)
F,Q814X(2)
F,1154insTC (2)
F,441delA (1)
F, 4326delTC (1)
F,Q552X(1)
F,3007delG (1)
F,2184insA (1)
F, 4010del4 (1)
F,3905insT (1)
F,1078delT(1)
F,E1104X (1)
F,3876delA (1)
F,4374+1G→T (1)
F,E585X (1)
F, E60X (1)
CFTR, cystic fibrosis transmembrane regulator; PI, pancreatic insufficiency; PS, pancreatic sufficiency.
1∆F508.
2Indeterminate.
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Genotypes and quantitative measures of pancreatic
function
Pancreatic function testing was performed in 95 patients (34
female), including 46 who have remained PS and 49 who were
either PI at diagnosis or developed PI after diagnosis. Table 3
shows pancreatic acinar and ductular function data according
to the functional classification system for CFTR gene
mutations. All patients who were homozygous or compound
heterozygous for mutations belonging to classes I, II, or III had
severely impaired pancreatic acinar and ductular function.
When expressed as a percentage of mean output reference
values (fig 1) there was a marked deficit of acinar capacity in
patients with class I, II, or III mutations compared with those
with class IV or V mutations (p<0.0001, Kruskal- Wallis, χ2, 4
df). Among patients with class IV and V mutations, acinar
function spanned a wide range of enzyme output from 18% of
mean control values to values well within the reference range.
Similarly, ductular function (fluid, bicarbonate, and chloride
secretion) was significantly lower among patients homo-
zygous or compound heterozygous for class I, II, or III muta-
tions than that observed in patients with mutations belonging
to class IV or V (p<0.01 for H2O; p<0.001 for HCO3
− and Cl−).
Patients in classes I, II, and III who were PS→PI were
indistinguishable from those who were PI at diagnosis. Acinar
output in the PS→PI group ranged from 0% to 14.3% of con-
trol values.
DISCUSSION
Attempts to elucidate the relation between genotype and the
various phenotypic manifestations of CF have been hampered
by the large number of CFTR gene mutations. In this study, the
frequency of the most common disease causing mutation
(∆F508) was very similar to the frequency of approximately
70% of all CFTR mutant alleles reported worldwide. The four
next most common mutations reported in this study (G551D,
G542X, 621+1G→T, and W1282X) each accounted for
Table 3 Pancreatic ductular and acinar secretion classified according to the functional consequences of CFTR gene
mutations
Functional
class n
Ductular function Acinar function
Fluid†
(ml/kg/h)
Bicarbonate‡
(mmol/kg/h)
Chloride‡
(mmol/kg/h)
Trypsin*
(U/kg/h)
Colipase*
(U/kg/h)
Total lipase*
(U/kg/h)
Class I 7 2.3 (1.5) 0.03 (0.02) 0.15 (0.14) 19 (42) 142 (201) 290 (388)
Class II 33 2.9 (2.4) 0.04 (0.04) 0.21 (0.33) 31 (63) 111 (197) 202 (276)
Class III 6 1.1 (0.87) 0.02 (0.02) 0.12 (0.07) 109 (256) 235 (483) 608 (1280)
Class IV 14 4.0 (2.8) 0.19 (0.2) 0.32 (0.12) 1032 (768) 9840 (10698) 12563 (10461)
Class V 10 4.8 (3.2) 0.12 (0.07) 0.36 (0.23) 1535 (1406) 12161 (13550) 16449 (15482)
Control 21 10.0 (3.9) 0.57 (0.22) 0.62 (0.3) 2291 (836) 13036 (5958) 19767 (8623)
Values are mean (SD).
CFTR, cystic fibrosis transmembrane regulator.
*p<0.0001 for Kruskal-Wallis, χ2, with 4 df.
†p=0.01.
‡p=0.001.
Figure 1 Quantitative pancreatic acinar and ductular secretion following intravenous cholecystokinin/secretin infusion in 70 patients,
expressed as a percentage of mean control values. (A) Trypsin; (B) lipase and colipase; (C) fluid output; and (D) bicarbonate (HCO3−) and
chloride secretion are shown. Box margins represent the 25th and 75th percentiles, with the horizontal bar representing the median. Whiskers
indicate the range of data. Comparison of classes I, II, and III with classes IV and V showed significant differences: p=0.01 (fluid), p=0.001
(bicarbonate and chloride), p<0.0001 (trypsin, colipase and lipase) by Kruskal-Wallis, χ2, with 4 df.
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between 1% to 3% of the mutations analysed. Twenty five
additional mutations, including the 5 thymidine variant in
intron 8,24 were identified in more than two families. Thus 31
CFTR gene mutations or variants which were identified in
more than one family accounted for 87.8% of all mutant alle-
les. Forty five additional mutations, or putative mutations,
which were identified in single patients, accounted for only
3.5% of mutant alleles. Despite our attempts to screen all
exons of the CFTR gene, 8.8% of mutant alleles remained uni-
dentified. These results are consistent with the recently
published CFTR mutation frequencies in the French
population.25
Recognising the frequency of uncommon or rare mutations
in CF, we evaluated the relation between genotype and
pancreatic phenotype by classifying individual patients’ CFTR
gene mutations. In this analysis, no assumptions were made
about the genotype based on the prior knowledge of the pan-
creatic phenotype, as genotypes were classified purely based
on their known or predicted consequences on CFTR mediated
anion secretion (fig 1). CFTR gene mutations belonging to
classes I, II, or III have varying effects on gene transcription,
mRNA translation, or intracellular trafficking of the nascent
protein. In functional terms, however, they would all be
expected to confer complete loss of cAMP regulated chloride
channel function. The results of the present study conclusively
indicate that homozygosity or compound heterozygosity for
mutations in classes I, II, and/or III is strongly associated with
severe pancreatic disease as the vast majority of these patients
were PI at diagnosis or progressed to PI after the diagnosis of
CF was established. By contrast, class IV and V mutations are
predicted to be less severe in terms of their effects on cAMP
regulated chloride channel properties. In our study, all
patients carrying at least one class IV or class V mutation were
PS at diagnosis, as measured by pancreatic function testing,
and all but one have remained PS. The single exception
appeared to develop PI due to progressive pancreatic damage
from chronic pancreatitis. In support of these results, data
from the European Epidemiology Registry of Cystic Fibrosis
showed that patients with class IV and V mutations were less
likely to be taking pancreatic enzyme supplements. However,
pancreatic function status was not objectively defined.26
A subset of patients who had undergone pancreatic stimu-
lation testing were also evaluated according to the predicted
consequences of their CFTR gene mutations. Not surprisingly,
patients who were homozygous or compound heterozygous
for mutations belonging to classes I, II, or III had severely
compromised acinar capacity (enzyme secretion of trypsin,
total lipase, and colipase). Among the PS→PI patients who
were PS when tested (n=14), enzyme secretion was also
severely compromised (approximating 0–14.3% of mean con-
trol values). The majority of these patients, who carried severe
CFTR gene mutation on both alleles, developed PI within two
years of life. In contrast, patients in this study with at least one
mild class IV or V mutation had significantly better pancreatic
acinar reserve, which in the majority has been maintained for
decades. Trypsin secretion in this group ranged from 11% of
mean control values to values within our adult reference
range.18
Pancreatic ductular secretion of anions (chloride and bicar-
bonate) and fluid was compromised in patients with CFTR
gene mutations belonging to all five functional classes. This
was expected because CFTR is normally expressed at high lev-
els in the intralobular and proximal ductal epithelia, and at
low levels in acinar cells.27 28 CFTR in the ductal epithelium
facilitates the secretion of an alkaline rich fluid which main-
tain the solubility of secreted enzymes. Complete loss of CFTR
function results in reduced intraluminal pH and a low
secretory volume.29 Scheele and colleagues29 have suggested
that reduced pH within the acinar lumen inhibits acinar
endocytosis of secretory granule proteins and reduces the
solubility of secreted luminal proteins within the acinar
lumen. Complete loss of CFTR function, due to mutations on
both alleles (classes I, II, or III) appears to induce rapid pan-
creatic atrophy through obstruction of secreted proteins
within the lumina of acini and small ducts. Postmortem stud-
ies of the CF pancreas from preterm infants and neonates
clearly demonstrate that this process begins in utero30 and
explains the rapid progression of pancreatic failure in early
infancy. Patients carrying at least one mutant allele belonging
to classes IV or V also had evidence of ductular dysfunction.
Chloride, bicarbonate, and fluid secretion was significantly
less than that observed in adult controls even in those with
normal acinar reserve. This observation supports our previous
hypothesis that a major component of anion and fluid
secretion is directly attributable to functional CFTR in pancre-
atic ductal epithelia.19 20 Obviously, mild class IV or V CFTR
gene mutations, which result in some residual ductular func-
tion, appear to protect the exocrine pancreas from complete
destruction at an early age.
There are several possible explanations for the heterogen-
eity of acinar reserve and ductular dysfunction among
patients carrying class IV and V mutations. Specific mutant
alleles belonging to classes IV and V may exhibit varying
degrees of chloride channel dysfunction, which in turn may
influence disease progression. Secondly, patients carrying at
least one class IV or V mutation may develop progressive pan-
creatic damage as a consequence of chronic pancreatitis.While
the prevalence of acute recurrent pancreatitis or chronic pan-
creatitis is low in patients with CF diagnosed on clinical
grounds,31 those with the PS phenotype appear to carry a high
risk of this complication.31
The limitations of this classification system are acknowl-
edged. Classification is not possible if a patient carries a
“putative”mutation or if the molecular properties of a disease
causing mutation are not understood. Furthermore, despite
extensive efforts to identify all CFTR gene mutations, one or
two mutant alleles remain unidentified in 17% of patients. A
small number of mutations (for example, G85E) are consid-
ered to be indeterminate due to their inconsistent effect on
pancreatic phenotype. Finally, it is more difficult to predict the
functional consequences in compound heterozygotes with
mutant alleles belonging to two different classes. Despite
these limitations, we have overcome previous assumptions
involved in analysing the relationship between genotype and
phenotype in CF by starting our analysis with the predicted or
known molecular consequences of the specific CFTR muta-
tions. We have demonstrated a strong relation between the
predicted functional effects of each genotype and pancreatic
phenotype in this patient cohort. Nevertheless, there were a
few exceptions. For example, two siblings with a class I muta-
tion (875+1G>C) had a PS phenotype. The precise reason for
this is unclear as 875+1G>C adversely affects the highly con-
served splice donor site sequence. One possibility is that alter-
native splicing nearby may preserve the effect of this mutant
allele.
In conclusion, we have demonstrated, using analysis of the
molecular consequences of CFTRmutations, that the CF geno-
type strongly correlates with the pancreatic phenotype.
Furthermore, we provide unique data indicating that CFTR
gene mutations correlate with quantitative measures of
pancreatic acinar and ductular function.
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